Sunshine Biopharma Inc. Accrued Income Taxes, Current
Sunshine Biopharma Inc. (SBFM) had Accrued Income Taxes, Current of $268.28 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedIncomeTaxesCurrent · last filed 2026-08-13
- 2026-06-30: Accrued Income Taxes, Current $268.28K.
- 2026-03-31: Accrued Income Taxes, Current $268.28K.
- 2025-12-31: Accrued Income Taxes, Current $268.28K.
- 2025-09-30: Accrued Income Taxes, Current $0.00.
| Period end | Accrued Income Taxes, Current |
|---|---|
| 2026-06-30 | $268.28K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $268.28K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $268.28K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 |
| 2025-06-30 | $258.16K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $228.12K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $268.28K 10-K · filed 2026-04-03 |
| 2024-09-30 | $254.97K 10-Q · filed 2024-11-05 |
| 2024-06-30 | $254.97K 10-Q/A · filed 2024-08-20 |
| 2024-03-31 | $254.97K 10-Q · filed 2024-05-20 |
| 2023-12-31 | $299.87K 10-K · filed 2025-04-01 |
| 2023-09-30 | $201.54K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $230.58K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $416.25K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $373.19K 10-K · filed 2024-03-28 |
| 2021-12-31 | $0.00 10-K · filed 2023-04-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |